Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Metsera, Inc. ( (MTSR) ).
On September 29, 2025, Metsera, Inc. announced positive results from two Phase 2b trials, VESPER-1 and VESPER-3, for their GLP-1 receptor agonist MET-097i, which shows promise for monthly dosing. The trials demonstrated significant weight loss and class-leading tolerability, with minimal gastrointestinal side effects. These results pave the way for a Phase 3 program to start in late 2025, with ongoing studies to further explore MET-097i’s potential in weight management and type 2 diabetes treatment. The company is also developing additional clinical programs based on MET-097i.
The most recent analyst rating on (MTSR) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Metsera, Inc. stock, see the MTSR Stock Forecast page.
Spark’s Take on MTSR Stock
According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.
Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.
To see Spark’s full report on MTSR stock, click here.
More about Metsera, Inc.
Average Trading Volume: 1,918,753
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.49B
For a thorough assessment of MTSR stock, go to TipRanks’ Stock Analysis page.